Close

FBR Remains Positive on Aviragen (AVIR) Amid Delay to Further BTA585 Phase 2a Enrollment; Affirms at 'Outperform'

May 27, 2016 12:20 PM EDT Send to a Friend
FBR & Co. affirmed Aviragen Therapeutics, Inc. (Nasdaq: AVIR) at Outperform after the company announced Thursday that it has voluntarily ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login